Physician profile
Ryan S Din
NPI 1679139133
$6,458.85
in general payments reported to CMS, 2019-2025
26 companies · $3,416 in 2025
The $3,416 reported for 2025 was more than what 82% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,000 · 2023: $800 · 2024: $1,243 · 2025: $3,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,405 · Grant: $800 · Education: $191 · Travel and Lodging: $63.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,404.86 |
| Grant | $800.00 |
| Education | $190.68 |
| Travel and Lodging | $63.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,189.38 | 2023-2025 | |
| Abbvie INC. | $1,067.84 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $635.85 | 2024-2025 | Tezspire, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $477.38 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $327.58 | 2025 | Nemluvio |
| Pfizer INC. | $191.81 | 2024-2025 | |
| Incyte Corporation | $186.29 | 2025 | Opzelura, Opzelura |
| Takeda Pharmaceuticals U.S.A., INC. | $184.69 | 2024-2025 | Eohilia, Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $174.21 | 2025 | Orladeyo |
| Grifols USA, LLC | $126.66 | 2024 | Xembify |
| Csl Behring | $124.80 | 2025 | Andembry, Hizentra |
| Glaxosmithkline, LLC. | $122.12 | 2024-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $96.60 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.02 | 2024-2025 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $91.70 | 2025 | Vtama, Hadlima, Renflexis |
| Gc Biopharma USA, INC. | $83.60 | 2024-2025 | Alyglo, Alyglo |
| Ars Pharmaceuticals Operations, INC. | $54.33 | 2025 | Neffy |
| Amgen INC. | $40.76 | 2025 | Tezspire |
| Ferring Pharmaceuticals INC. | $38.41 | 2025 | Rebyota |
| Genentech USA, INC. | $30.08 | 2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $29.74 | 2025 | Dawnzera |
| Optinose US, INC. | $28.41 | 2025 | |
| Pharming Healthcare, INC. | $26.96 | 2025 | Ruconest |
| Aimmune Therapeutics, INC. | $19.40 | 2025 | Zenpep |
| Kedrion Biopharma, INC. | $17.23 | 2025 | Gammaked, Koate, Kedrab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Din listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.